The objective of this study is to establish a registry of patients with thalassemia to allow
for both cross-sectional and longitudinal assessment of laboratory values and outcomes and to compare how different treatments impact these variables. Patients with a diagnosis of a clinically significant alpha or beta thalassemia syndrome who are seen at CHOP or UPenn Thalassemia Treatment Centers will be approached for enrollment.
